StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

Equities researchers at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Wednesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Down 2.2 %

NURO opened at $3.93 on Wednesday. The business has a 50 day moving average of $4.00 and a 200-day moving average of $3.87. The stock has a market capitalization of $8.02 million, a price-to-earnings ratio of -0.86 and a beta of 2.20. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million during the quarter. During the same period in the previous year, the business posted ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.